Carcaboso A M, Hernández R M, Igartua M, Rosas J E, Patarroyo M E, Pedraz J L
Pharmacy and Pharmaceutical Technology Laboratory, Universidad del País Vasco (UPV-EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain.
Vaccine. 2004 Mar 29;22(11-12):1423-32. doi: 10.1016/j.vaccine.2003.10.020.
The immunogenicity of the synthetic malaria vaccine SPf66 has been recently improved by the application of new adjuvants as QS-21 saponin or poly-D,L-lactide-co-glycolide (PLGA) polymers. The search for less invasive administration routes made us test the immunogenicity of SPf66-loaded microparticles by the nasal route in Balb/c mice. We report here that the intranasal administration of the adequate PLGA vaccine formulations greatly improves and maintains higher antibody levels compared to the conventional alum adjuvant and to the administration of the particles by other routes (subcutaneous, oral). Systemic immune responses were characterized as mixed Th1/Th2-type: IFN-gamma and IgG2a isotype were found as signs of Th1 activation, whilst IgE and IgG1 secretions indicate Th2 response. Since both types of response have been associated to protective immunity in malaria, we postulate that this new approach supposes an advantage over the traditional adjuvants and routes.
合成疟疾疫苗SPf66的免疫原性最近通过应用新的佐剂如QS-21皂苷或聚-D,L-丙交酯-共-乙交酯(PLGA)聚合物而得到改善。对侵入性较小的给药途径的探索促使我们在Balb/c小鼠中通过鼻腔途径测试负载SPf66的微粒的免疫原性。我们在此报告,与传统的明矾佐剂以及通过其他途径(皮下、口服)给药的微粒相比,经鼻给予适当的PLGA疫苗制剂可大大提高并维持更高的抗体水平。全身免疫反应的特征为Th1/Th2混合型:发现IFN-γ和IgG2a同型是Th1激活的标志,而IgE和IgG1分泌则表明Th2反应。由于这两种类型的反应均与疟疾的保护性免疫相关,我们推测这种新方法相对于传统佐剂和途径具有优势。